Stability
stabilizing
bound vs apo tetramer
tetramer-locking direction, matches the clinical record
Transthyretin (TTR) L55P is the most aggressive TTR amyloidogenic mutation. Tafamidis binds the TTR tetramer and blocks dissociation, the first step in amyloidogenesis. This page shows what a Troopir engine run produces when asked to rank tafamidis as a TTR L55P stabilizer.
One run on TTR L55P, comparator tafamidis. Compatibility 0.87, a strong stabilizer. Deterministic, bit-identical across reruns. Illustrative values, shown for layout.
A real Troopir engine run on this target returns the five indicators above and a single compatibility score, and nothing more. No layer breakdowns, no per-residue energy tables, no internal parameters, no methodology notes. The output is deterministic; the same sequence and comparator produce the same result across reruns.
For TTR L55P paired with tafamidis the direction is unambiguous: a strong, tetramer-locking stabilizer that engages the known T4-binding pocket and clears every benchmark check. The same call the clinical record reached, reproduced from sequence and ligand alone.
A real evaluator run uses your sequence, your comparator (or up to six comparators), and your indication. Engine output is delivered as a canonical report URL of the form https://troopir.com/vault/uploads/reports/{run_id}.html under your evaluator credentials.